bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Business Wire•15/10/2026•08:00 ET
0
Key Highlights
- ➤CHEST 2026 presentation will address CyPath Lung’s role in pulmonary nodule risk stratification
- ➤CyPath Lung reported 92% sensitivity, 87% specificity, and 99% negative predictive value
- ➤New asthma and COPD inflammation test remains an investigational research program
- ➤Medical and Scientific Advisory Board will discuss federal expansion and longitudinal clinical study
Expert Statements
Gordon H. Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies
“With increased lung cancer screening rates, more incidental findings and AI's ability to mine medical records, we are getting better at finding pulmonary nodules. But that is just the first step.”
Gordon H. Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies
“By analyzing cells from the lung microenvironment, CyPath Lung's binary result – either likely or unlikely malignancy – provides new information that complements imaging, clinical risk models and physician gestalt to help inform decisions about further testing, biopsy or continued surveillance.”
Maria Zannes, President and CEO of bioAffinity Technologies
“Our Medical and Scientific Advisory Board’s extensive experience in real-world pulmonary practice and lung health is directly aligned with our corporate and clinical mission to improve outcomes for patients by detecting lung cancer and other lung diseases early when treatment is most effective.”
Maria Zannes, President and CEO of bioAffinity Technologies
“We are always grateful for their expert perspectives that inform our research priorities and clinical applications.”
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung
Get started
Create a free account to read the full story.